 CAMBRIDGE, Mass., Dec. 16, 2020 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. NASDAQ: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has been selected for addition to the NASDAQ Biotechnology Index Nasdaq: NBI, effective prior to market open on Monday, December 21, 2020. 